Bioengineering

Elliot Chaikof, MD, PhD

Elliot Chaikof, MD, PhD

Beth Israel Deaconess Medical Center
Harvard Medical School
Wyss Institute for Biologically Inspired Engineering

Elliot L. Chaikof, MD, PhD, has promoted alliances of clinicians, engineers, chemists, and biologists and in the process developed biologically-inspired materials, devices, and pharmacotherapeutics based upon the principles of molecular engineering and nanofabrication technologies. These endeavors have enabled advances in cell-based therapies, artificial organs, and engineered living tissues, which define the evolving field of Regenerative Medicine.

Jeffrey Karp, PhD

Jeffrey Karp, PhD

Brigham & Women's Hospital
Harvard Medical School
Harvard-MIT Division of Health Sciences and Technology

Dr. Jeff Karp is an Associate Professor at Brigham and Women's Hospital, Harvard Medical School, and is Principal Faculty at the Harvard Stem Cell Institute and affiliate faculty at MIT through the Harvard-MIT Division of Health Sciences and Technology.

His research harnesses materials science and stem cell biology to solve medical problems with emphasis on nanoscale/microscale materials and bio-inspired approaches.

Kevin Kit Parker, PhD

Kevin Kit Parker, PhD

Harvard School of Engineering and Applied Sciences
Wyss Institute for Biologically Inspired Engineering

My research team's focus is on understanding cellular mechanotransduction in the heart.

Khalid Shah, PhD

Khalid Shah, PhD

Massachusetts General Hospital
Harvard Medical School

Successful treatment of brain tumors remains one of the greatest challenges in oncology. The recognition that different stem cell types, including neural stem cells (NSCs) can integrate appropriately throughout the mammalian brain following transplantation has unveiled new possibilities for their use in neural transplantation. Our laboratory has shown that different stem cell types home to sites of cerebral pathology and thus can be armed with therapeutic transgenes, a strategy that can be used to inhibit tumor growth by targeting angiogenesis or selectively inducing apoptosis in proliferating tumor cells in the brain.